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CD4 is widely known as the HIV receptor, but is 
insufficient to allow viral infection. Recently, members 
of the family of chemokine receptors have been 
identified as the missing co-receptors, which act with 
CD4 to allow the virus to enter cells. These discoveries 
open up the possibilities of novel therapeutic strategies 
to combat HIV infection and AIDS. 
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One of the central questions in AIDS research has been 
how the human immunodeficiency viruses, HIV-l and 
HIV-Z, fuse with and infect human cells. Early on in the 
study of these viruses, it was shown that HIV-l primarily 
infects cells expressing the CD4 cell-surface marker 
(reviewed in [l]). CD4 is expressed predominantly on 
the surface of ‘helper’ T-cells and macrophages, cells 
that are known to be infected by HIV. The hypothesis 
that emerged was that the viral envelope glycoprotein 
gplZO/gp41 forms a complex with CD4, leading to 
fusion of the membranous envelope of the virus with 
the plasma membrane of the host cell. But although 
CD4 and gp120 can form a complex, murine cells 
expressing human CD4 will not fuse with HIV-l. 
Clearly, the formation of this complex alone is not suffi- 
cient to allow viral fusion, suggesting that there may be 
a second or co-receptor molecule [Z]. 
Understanding the viral fusion process has been further 
complicated by the fact that different strains of HIV-l 
(and other primate lentiviruses, such as HIV-Z or SIV) 
show distinct cell tropisms. In other words, the viruses 
exhibit preferences for specific cell types. For example, 
HIV-l strains that have been cultured in the laboratory in 
T-cell lines tend to infect primary T-cells, but not mono- 
cytes or macrophages, and are therefore known as T-cell 
‘adapted’ strains. But many primary viral isolates infect 
monocytes, macrophages and primary T-cells, but not 
transformed T-cell lines. 
The virus strains vary not only in tropism, but also in 
their ability to induce syncytia in culture (multinuclear 
cells formed by cell to cell fusion). These strains are pref- 
erentially isolated at late clinical stages of the infection 
and are a hallmark of late stage AIDS pathology. Within 
an HIV-positive individual, it seems that the strains of 
HIV-l that initially establish a persistent infection are 
macrophage-tropic, non-syncytium-inducing (NSI) strains. 
Later, T-cell-tropic, syncytium-inducing (SI) strains of 
virus emerge [3]. These strains seem to be associated 
with progression to the clinical symptoms of AIDS. 
These changes in tropism and the NSI/SI switch are asso- 
ciated with changes in the amino acid sequence of the 
envelope glycoprotein and in the entry and fusion proper- 
ties of the virus [4,5], suggesting that different viral strains 
might use different co-receptors. But the nature of these 
co-receptors was, until very recently, a mystery. 
The connection between chemokines and HIV 
As early as 1988, it had been shown that CD8+ T-cells 
(which do not carry the CD4 cell surface marker) could 
produce a soluble factor, CD8+-derived antiviral factor 
(CAF), that inhibited HIV infection of other cells [6]. 
Recently, Cocchi et&. [7] examined a range of IL-Z-stimu- 
lated, HTLV-l-transformed CD8+ T-cell lines for the pro- 
duction of soluble factors that prevented infection of cells 
with HIV-l,,,. This is a macrophage-tropic strain of the 
virus, with biological properties resembling those of some 
NSI primary isolates. The factors responsible for inhibi- 
tion of infection were purified by high-pressure liquid 
chromatography and identified as the chemokines 
MIP-la, MIP-1B and RANTES [7]. Purified recombinant 
chemokines were found to block the entry of NSI viruses 
into primary adherent macrophage populations [7]. Some 
individuals who are HIV-negative despite multiple high 
risk exposures to HIV also have high circulating levels of 
these chemokines [8], reinforcing the notion that these 
factors are relevant to the infection in viva. 
The co-receptor for HIV fusion has been avidly sought, 
but claims for its identification have not stood the test of 
time. But a novel cell-cell fusion assay, reported a few 
months ago, has finally made it possible to identify a co- 
receptor for SI strains of HIV [9]. The assay used vaccinia 
virus to express the HIV envelope glycoprotein on fibro- 
blasts. These cells were tested for fusion with cells 
expressing CD4 and proteins encoded by a human cDNA 
library. The pools of cDNAs screened were progressively 
subdivided, until a single cDNA was identified that 
allowed fusion. The cDNA responsible has a high degree 
of sequence identity with the seven-transmembrane- 
spanning (7TM) G-protein-coupled receptor class of pro- 
teins. Because of its ability to support viral fusion, it was 
named fusin. It had previously been cloned as an orphan 
receptor, and was named HUMSTR, LCR-1 or LESTR 
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[lo-121. Its ligand has not yet been determined, despite 
intensive efforts by many laboratories [12]. The amino 
acid sequence for fusin shows highest identity with those 
of the chemokine receptors, and the average identity 
level is highest for the class of chemokines dubbed CXC 
(see Fig. 1). Fusin appears to be selective for those strains 
of HIV that are adapted to T-cell lines, and does not seem 
to act as a co-receptor for NSI viruses. But since MIP-lo, 
MIP-1B and RANTES can block the entry of NSI strains 
of HIV into target cells [7,8], it seemed plausible that a 
chemokine receptor might be involved here too. 
What are chemokines? 
Chemokines are a superfamily of small proteins (with 
molecular masses of S-10 kDa) that are involved in a 
number of inflammatory processes, including the selec- 
tive activation and recruitment of leukocytes [13,14]. 
More than 30 human members of the superfamily have 
been identified so far. They show limited amino acid 
sequence identity - often as low as 20 % - but NMR 
spectroscopy and X-ray crystallographic studies show that 
their three-dimensional structures are well conserved. 
Almost all chemokines contain four distinctive conserved 
cysteine residues, forming two intramolecular disulfide 
bridges. The superfamily can be divided into three 
groups based on the spacing of these cysteine residues 
(see [14] for an alignment). In CXC chemokines, the first 
two cysteines are separated by one amino acid (X). The 
CXC chemokines seem to be primarily important in acute 
Figure 1 
inflammation, and activate neutrophils. Two receptors for 
CXC chemokines have been cloned, CXCR-1 and 
CXCR-2 (also known as IL-8RA and B, respectively). In 
the CC chemokines, the first two cysteines are adjacent; 
these proteins do not generally appear to act on human 
neutrophils, but affect leukocyte populations such as 
monocytes, T-cells, eosinophils and basophils. They are 
thought to be involved in inflammatory diseases such as 
asthma, atherosclerosis and arthritis. MIP-lo, MIP-1B 
and RANTES are all CC chemokines. Five receptors for 
the CC chemokines have so far been identified (see 
Table 1 and [14]). Other chemokines such as lympho- 
tactin, with only one disulfide [15], and another, with a 
CXXXC spacing (T.N.C.W. etal., unpublished data), have 
been described, but their receptors are unknown. 
Throughout this review, a simplified nomenclature for 
chemokine receptors, proposed at the recent Gordon 
Research Conference (Chemotactic Cytokines, June 
23-28, 1996), will be used. Under this system, the CC 
chemokine receptors are termed CCRl-5, and the IL-8 
receptors A and B are termed CXCR-1 and CXCR-2. 
Towards a molecular hypothesis -the identification of CCR5 
The finding that inhibition of infection by monocytotropic 
strains of HIV was associated primarily with RANTES, 
MIP-lo and MIP-1B and not other chemokines concen- 
trated the search on a chemokine receptor shared by these 
three ligands (Table 1). The clone for human CCRS, when 
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7 Dendrogram showing the similarities between the different human, murine and 
virally encoded (human cytomegalovirus and 
herpes virus saimiri), and human orphan 
protein sequences. The sequences cluster in 
terms of the level of identity of pairs of amino 
acids. The further to the right that the branch 
points are shown on the diagram, the more 
similar the two proteins are. There is a clear 
grouping of the CC chemokine receptors. It 
is tempting to speculate that all the receptors 
in the lower half are CXC chemokine 
receptors, since the group spans known 
CXC chemokine receptors such as CXCR-1 
and the virally encoded ECRF-3. This 
similarity would imply that the ligand for fusin 
is a CXC chemokine. Details of sequences 
used are given in Power and Wells [14]. 
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Table 1 
The human chemokine receptors and their murine homologues. 
Receptor Ligand (Kd) Murine 
homolooue 
CXC chemokine receptors 
CXCRl (IL-8RA) IL-8 (1.7 nM) 
CXCR2 (IL-8RB) IL-8 (0.8 nM), GROa (1.2 nM), 
NAP-2 
CC chemokine receptors 
CCRl MIP-lo (10 nM), RANTES (0.6 nM), 
MCP-3 (0.7 nM) 
CCR2b MCP-1 (0.26 nM), MCP-3 (6 nM) 
CCR3 Eotaxin (0.5 nM), MCP-4, MCP-3, 
RANTES 
CCR4 MIP-lo (14 nM), RANTES (9 nM), 
MCP-1 
CCR5 MIP-la, MIP-18, RANTES 
Promiscuous and virally encoded receptors 
DARC IL-8 (20 nM), GROo (24 nM), 
RANTES (42 nM), MCP-1 (34 nM) 
HCMV US 28 RANTES (3.4 nM), MCP-1 (6.1 nM), 
MIP-lo (2.5 nM), MIP-18 (5.1 nM) 
HSV ECRF3 GROo, NAP-2, IL-8 
Orphan receptor 
Fusin ? 
none 
mull-8R 
muCCR1 
muCCR2 
muCCR3 
mCCR4A 
mCCR5 
mDARC 
mLCR 
The CC chemokine receptors are given here as CCRl-5 in keeping 
with a recently proposed convention (Gordon Research Conference 
on Chemotactic Cytokines, June 23-28, 1996). For details of ligand 
binding and the receptor sequence alignments, see 1141. 
stably transfected in a CHO cell line, gave responses in a 
microphysiometer assay to MIP-la and MIP-LB and 
RANTES, but not to other CC or CXC chemokines [16] 
and was thus a candidate for the co-receptor for primary 
NSI strains of virus. 
Figure 2 
Studies by ‘rive groups [17-211 on the role of CCR5 in 
HIV infection appeared in the literature in the same 
week. These reports showed that, in the presence of 
CD4, macrophage-tropic NSI strains of HIV-l such as 
JRFL, ADA and BAL can use CCR5 as a co-receptor for 
fusion. In contrast, CCR5 cannot act as a co-receptor for 
several T-cell-tropic, SI strains of the virus. Furthermore, 
expression of CCR5 plus CD4 allows the productive 
infection of nonprimate cells. 
Switching chemokine receptors 
The fact that NSI strains of HIV give way as the disease 
progresses to SI strains, in the process presumably switch- 
ing co-receptors from CCRS to fusin, raises a number of 
interesting possibilities about the way that the virus causes 
disease. Transmission of HIV by sexual contact is likely to 
lead to the infection of CD4+ cells associated with the 
vaginal or rectal epithelium. Of the cell types in these 
tissues, Langerhans cells, a form of CD4+ antigen-present- 
ing dendritic cell that can migrate from the skin and other 
epithelia to the lymph nodes, are particularly interesting. 
These cells are known to be infected by HIV-l, and their 
migratory properties may well facilitate the transfer of virus 
to the lymphoid tissue; they may also act as reservoirs for 
the virus during the prolonged asymptomatic phase of the 
infection [22,23]. During this phase, virus production and 
infection of CD4+ T-cells continues but is largely con- 
trolled by the immune system [24]; the viruses active in 
this phase may use CCR5 as the primary co-receptor. As 
infection progresses, however, mutant viruses, in particular 
viruses with changes in the Vl, V2 and V3 loop regions of 
the gp120 subunit of the envelope glycoprotein, are contin- 
ually generated and SI viruses that exhibit a clear prefer- 
ence for fusin as the co-receptor eventually emerge (Fig, 
2). As few as two mutations are required to achieve this 
switch in tropism [8,25]. What drives this switch is unclear; 
it is possible that the switch in co-receptor may be required 
to allow the virus to escape the protective effects of circu- 
lating MIP-la, MIP-1B and RANTES. Predictions based 
on the mutation rate of the virus suggest that viruses 
with an altered co-receptor preference will emerge within 
Mutation in gpl20 can change the tropism of 
HIV for particular cell types. The strains of 
HIV-l that initially establish persistent 
infection are macrophage-tropic NSI strains 
and recognize CD4 and the co-receptor 
CCR5 on the surface of target cells. Mutation 
of as few as two amino acids in gpl20 
produces a T-cell tropic SI strain of virus. 
w 
Mutations 
in viral envelope 
glycoprotein 
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weeks of infection; why it takes several years or more for 
these viruses to become dominant is unclear. 
The simple model that there are only two types of HIV, 
one using CCRS and the other using fusin, is already 
breaking down, however. Some primary clinical isolates of 
HIV can use CCR3 as their co-receptor [18]. CCR3 was 
originally thought to be restricted to eosinophils, but is 
now known to be expressed on monocytes and T-cells as 
well. In addition, a dual tropic primary HIV-l isolate, 89.6, 
has been identified that can induce cells expressing any 
one of a number of chemokine receptors (CCRS, CCRZb, 
fusin or CCRS) to form syncytia [‘ZO]. It is possible that 
some receptors may allow cell fusion and syncytium for- 
mation, but be less effective in allowing entry of a viral 
particle. This appears to be the case with strains of HIV-Z, 
which also often show overlapping host cell tropisms and 
broader host cell ranges than those of HIV-l strains. 
Fusion can be seen between cells bearing the envelope 
glycoprotein from HIV-Z,,, and those bearing CCRZb, 
CCR3, or CCR4, and to a lesser extent fusin or CXCR-2. 
But as yet only CCR3, fusin and CXCRZ have been 
shown to support infection by this strain of virus (R. Bron. 
etal., unpublished data). 
A model for the action of chemokine receptors in viral 
fusion and entry 
At this stage, one can only speculate on how the viral 
envelope glycoprotein interacts with chemokine recep- 
tors and with CD4 to facilitate viral infection. It is known 
that when the viral envelope glycoprotein binds to CD4 
there can be a conformational change resulting in the 
increased exposure of the V3 loop [26] (Fig. 3). The V3 
loop is a disulfide-bridged, 30 amino acid region, which is 
exposed on the surface of the viral gp120 [27]. Since 
strains of virus that differ in sequence in this region can 
show different tropisms and may well use different co- 
receptors, one might expect the V3 loop to be important 
in the interaction with the co-receptor. Binding of gplZ0 
to the co-receptor might cause a second conformational 
change, this time in the transmembrane subunit of the 
envelope glycoprotein (gp41), leading to exposure of the 
hydrophobic amino-terminal region of gp41 and its inser- 
tion into the host-cell membrane (Fig. 3). This mecha- 
nism for initiating membrane fusion may be similar to 
that of influenza virus, in which a conformational change 
in the haemagglutinin envelope protein is induced by low 
pH [28]. Insertion of the amino-terminal hydrophobic 
domain of gp41 into the cell membrane may provide the 
driving force to start the fusion of the viral and cell mem- 
branes. The interaction between gp120, CD4 and the 
chemokine receptor could be critical in the initiation of 
this process. This opens up the possibility that individu- 
als who express abnormal levels or mutant forms of CCR.5 
would be resistant to HIV-l infection, and may offer a 
further explanation of why some individuals who have 
Figure 3 
Conformational 
change in gp120 
Interaction with 
chemokine receptor, 
gp41 conformational change 
Viral fusion 
1 : 
A model for the action of chemokine receptors in viral fusion and entry. 
Binding to CD4 can produce a conformational change in gpl20, 
exposing the V3 loop and possibly other variable regions in the viral 
envelope glycoprotein. Binding to the co-receptor might cause a 
second conformational change, this time in gp41, leading to exposure 
of the hydrophobic amino-terminal region and insertion into the host- 
cell membrane. The fusion complex presumably involves multiple 
envelope glycoprotein-host cell interactions. This may provide the 
driving force to start the fusion of the viral and cell membranes. 
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had multiple high risk exposures to the virus do not 
become infected. 
Given all of the above, why is HIV unable to infect non- 
primate cells? One would predict that the murine homo- 
logues of the chemokine receptors cannot function as fusion 
receptors, although this has not yet been shown. The 
murine CCR5 gene has been cloned, and its protein product 
has been shown to bind MIP-lo, MIP-1P and RANTES, 
just like its human counterpart [29]. In addition, it has 96 % 
amino acid similarity and 86 % identity to the human 
protein. Similarly, the human sequence for LESTR has 
91 % identity to the rat receptor and 93 % identity to the 
bovine receptor. Most of the differences are clustered in the 
extracellular loops, but alignments of the various fusin and 
CCR5 sequences have not yet given insight into the ques- 
tion of why the rodent receptors should not act as a co-recep- 
tor. However, since only a few amino acid changes in gp120 
are needed to change the viral tropism, as discussed above, 
perhaps the changes required to make CCR5 incompetent 
for gp120 binding are equally subtle. Mapping of the regions 
of the receptor essential for fusion might thus require analy- 
sis down to the level of individual amino acid changes. 
Figure 4 
How do chemokine ligands block viral fusion? 
Perhaps the most encouraging aspect of the discovery of 
the HIV co-receptors is that infection can be blocked by 
the use of the receptor ligands - MIP-la, MIP-l/3 and 
RANTES for strains that use CCR5 as a co-receptor and 
eotaxin for those that use CCR3. The mechanism by 
which these chemokines can prevent HIV-l from entering 
cells is still far from clear. The simplest explanation is that 
the binding site of the gplZ0 glycoprotein on the 
chemokine receptor overlaps with the ligand itself, and 
prevents the association of the chemokine receptor with 
gp120 or CD4 purely by steric means (Fig. 4a). However, 
the entry of some macrophage-tropic strains of HIV-l into 
some cell lines could not be completely blocked with 
CCR5 ligands, suggesting that this interaction may not 
always be sufficient to block fusion [19]. Also, of the 
known ligands of CCR3 (eotaxin, MCP4, MCP3 and 
RANTES) only eotaxin has so far been shown to block the 
use of CCR3 by the YU2 strain of HIV-1 [18]. 
It is possible that inhibition of HIV-l entry results instead 
from desensitization and down-regulation of the receptors 
(Fig. 4b). It is known that the chemokine receptors CXCRl 
Blockade of viral infection by chemokines. 
There are two distinct mechanisms by which 
the addition of a chemokine ligand can block 
the infection by a virus. (a) A simple steric 
block. The chemokine prevents the formation 
of a productive complex by blocking off part 
of the chemokine receptor and preventing it 
from being available to the viral glycoprotein 
gpl20 for complex formation. (b) The 
chemokine activates and then desensitizes 
the receptor (a process usually involving a 
conformational change and the 
phosphorylation of the intracellular regions of 
the protein), leading to internalization of the 
receptor. The result is that the chemokine 
receptor either cannot access the correct 
conformation to form a complex with gpl20 
and CD4, or simply is no longer present on 
the cell surface. 
(a) 
* 
Chemokine physically 
blocks virus-cell fusion 
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and ‘2 can be rapidly desensitized and internalized with a 
half life of 3 min at 37 “C following ligand binding [30]. We 
have seen similar effects for CCRl (A.E.1.P and Roberto 
Solari, unpublished data). It is tempting to speculate that 
the high levels of RANTES, MIP-lcx and MIP-1B found in 
the plasma of nonprogressors may lower the level of active 
receptor present on the surface of macrophages. Once the 
ligand for fusin is identified, it will also be interesting to see 
whether it is over-expressed in individuals who are infected 
but progress particularly slowly to symptomatic AIDS. As 
fusin is specific for the SI strains, one would expect the 
fusin ligand to be more effective in inhibiting the later 
stages of disease progression than in blocking the initial 
infection in cases of transmission by sexual contact. 
What is the ligand for fusin? 
A large number of important questions remain to be 
addressed, including the identification of the natural 
human ligand for fusin. Early attempts to define a ligand 
for fusin (then called LESTR [12]) using radioligand 
binding assays, failed to show any significant binding by 
11 known chemokines. However, it has been surprisingly 
difficult to identify ligands for chemokine receptors using 
assays of this kind. The ligands for CKR-2, -3, -4 and -5 
were all identified in physiological response assays, such 
as calcium fluxes or microphyisiometry. Only after a ligand 
had been identified by these methods was it possible to 
determine conditions under which it was possible to show 
ligand binding and displacement. Furthermore, there are 
now at least 30 known human chemokines [31,14], includ- 
ing many that have only been identified as the products of 
expressed sequence tags (ESTs). It is possible that the 
fusin ligand could be one of these products. The align- 
ment of the sequence of fusin with that of the CXC 
chemokine receptors suggests that the fusin ligand may be 
one of the recently identified, novel CXC chemokines. 
Possibilities for therapeutic intervention 
Before we can determine the type of chemokine-receptor- 
binding agents that would be therapeutically useful, we 
need to understand the mechanism by which some 
chemokines can block virus-target cell fusion. If chemo- 
kine ligands act by causing the desensitization and inter- 
nalization of the receptor, that would suggest that a 
chemokine receptor agonist is required. As most of the 
chemokines were originally identified because of their 
roles in recruiting cells during an inflammatory response, 
the use of chemokine receptor agonists as anti-viral agents 
may have unwanted inflammatory side effects. But the 
injection of MIP-la into patients does not cause inflam- 
mation [32], suggesting that the action of chemokines in 
recruiting and activating inflammatory cells requires that 
the cells are first ‘primed’ by other agents. The data of 
Paxton et ak. [S] also suggest that some individuals may 
produce naturally high levels of chemokines, apparently 
without inflammatory side effects. 
Traditionally, it has been very hard to find small molecules 
that block protein-protein interactions such as the interac- 
tion of cytokines with their receptors [33]. This is mostly 
because a typical protein-protein interface has a large 
surface area, with the contributions to the binding energy 
delocalized across this area. A small molecule would there- 
fore have to cover a relatively large surface area to gain suf- 
ficient binding energy either to mimic, or to block the 
protein-protein interaction. In the case of the chemokines, 
however, the receptors are of the 7TM class. It is therefore 
far more likely that small molecules can be found to modu- 
late the chemokine-receptor interaction, since other recep- 
tors of this class have proved amenable to such approaches. 
The case of C5a (complement factor 5a), a small protein of 
similar size to chemokines (75 amino acids) that binds to a 
7TM receptor, is a good example [34]. C5a binds to its 
receptor in two steps, using two binding sites. The initial 
recognition uses one binding site, and triggers a conforma- 
tional change in the flexible tail of C5a that allows binding 
to the main body of the receptor. It is this conformational 
change that presumably drives the activation of the G 
protein and the resultant signalling process. In the case of 
the C5a receptor, the residues important for signalling are 
localized in the flexible tail. It has been relatively easy to 
use this region of C5a to find small molecules that block 
the interaction between the ligand and its receptor. There 
are many parallels between the chemokine-receptor inter- 
action and the CSa-receptor interaction, including sugges- 
tions of a two-site mechanism, and it is almost certainly 
also true that a conformationally flexible region, which con- 
tains the residues that are essential for the recognition of 
the receptor, changes on receptor binding [35]. Although 
no small molecule agonists or antagonists of chemokine 
receptors have been described to date, the importance of 
these receptors in the inflammatory process means that 
many groups are currently actively involved in the search. 
Thus, if the inhibitory effect of chemokines on viral fusion 
is due to activation and down-regulation, it seems very 
likely that some candidate inhibitors will be found. 
If chemokines prevent viral fusion by a purely steric block- 
ade of the chemokine receptor/gplZO/CD4 complex, how- 
ever, the problem is very different. The ability of a small 
molecule to block the interaction would then depend on 
just how localized the gplZO-binding site on the chemo- 
kine receptor is. Under these circumstances, finding small 
molecule antagonists for the 7TM receptors may be no 
easier than it would be for other protein targets [35]. 
The other therapeutic question is which target to choose. 
Is it better to try to intervene at the primary infection 
stage, by blocking CCR5 and thus preventing the initial 
infection by NSI viruses, or to attempt to inhibit the 
spread of SI viruses via fusin? Both may have advantages. 
As SI viruses emerge late in infection and are associated 
with a more rapid clinical decline [3], preventing T-cell 
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infection by SI viruses may delay or prevent the emer- 
gence of symptoms in seropositive patients. On the other 
hand, an agent that blocks the infection of macrophages 
and dendritic cells might be effective early in the course 
of infection. 
Any effort to find anti-HIV agents faces the problem that 
the virus may be able to mutate to a resistant form. Since 
there is a wide variety of chemokine receptors, it is reason- 
able to assume that when a therapy based upon chemokine 
receptors is tested clinically, mutant viruses will be 
selected that can use different chemokine receptors as 
fusion co-factors. The future therapy of HIV infection and 
AIDS will almost certainly continue to depend on the use 
of multiple treatments. But the addition of chemokine 
receptors as a novel, and somewhat unexpected, target 
clearly improves the chances of being able to maintain 
HIV-infected individuals in an asymptomatic state, and 
perhaps even to reverse the progression to AIDS. 
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